Jefferies puts Accentia at buy

Accentia Biopharma was rated at buy by Jefferies & Co., Inc. analyst Adam Walsh on news that SinuNase receives Fast Track status from the Food and Drug Administration, the first product for chronic sinusitis to receive the designation. Shares of the Tampa, Fla., pharmaceutical company were up $0.38, or 6.02%, at $6.69 on volume of 16,905 shares versus the three-month running average of 29,503 shares. (Nasdaq: ABPI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.